Aditxt, Inc. – NASDAQ:ADTX
Aditxt stock price today
Aditxt stock price monthly change
Aditxt stock price quarterly change
Aditxt stock price yearly change
Aditxt key metrics
Market Cap | 3.08M |
Enterprise value | N/A |
P/E | -0.01 |
EV/Sales | -5.16 |
EV/EBITDA | 0.10 |
Price/Sales | 1.49 |
Price/Book | 0.10 |
PEG ratio | N/A |
EPS | -108.77 |
Revenue | 506.44K |
EBITDA | -31.26M |
Income | -41.12M |
Revenue Q/Q | -63.51% |
Revenue Y/Y | -46.22% |
Profit margin | -5100.99% |
Oper. margin | -4837.8% |
Gross margin | 20.93% |
EBIT margin | -4837.8% |
EBITDA margin | -6173.62% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAditxt stock price history
Aditxt stock forecast
Aditxt financial statements
| Jun 2023 | 220.97K | -5.68M | -2571.3% |
|---|---|---|---|
| Sep 2023 | 124.48K | -9.74M | -7828.91% |
| Dec 2023 | 81.29K | -10.96M | -13491.53% |
| Mar 2024 | 79.68K | -14.72M | -18486.1% |
| 2025 | 1.2M | -27.80M | -2317.31% |
|---|---|---|---|
| 2026 | 1.26M | -28.27M | -2244.4% |
| 2027 | 1.32M | -28.76M | -2173.86% |
| 2028 | 1.38M | -29.24M | -2105.61% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-14 | -5.99 | -48.77 |
|---|
| Jun 2023 | 7293783 | 11.16M | 153.05% |
|---|---|---|---|
| Sep 2023 | 8225559 | 12.44M | 151.32% |
| Dec 2023 | 44578327 | 28.53M | 64% |
| Mar 2024 | 27975521 | 18.19M | 65.03% |
| Jun 2023 | -3.28M | -2 | 3.07M |
|---|---|---|---|
| Sep 2023 | -8.03M | -9.35K | 9.59M |
| Dec 2023 | -3.30M | 0 | 1.75M |
| Mar 2024 | -5.96M | 0 | 5.95M |
Aditxt alternative data
| Aug 2023 | 61 |
|---|---|
| Sep 2023 | 61 |
| Oct 2023 | 61 |
| Nov 2023 | 61 |
| Dec 2023 | 61 |
| Jan 2024 | 61 |
| Feb 2024 | 61 |
| Mar 2024 | 61 |
| Apr 2024 | 61 |
| May 2024 | 47 |
| Jun 2024 | 47 |
| Jul 2024 | 47 |
Aditxt other data
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 0 | 20800 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BNP PARIBAS SECURITIES CORP | Aditxt Inc | 20,800 | $33.23 | $691,142 | ||
Purchase | ALBANNA AMRO A. officer: Chief Ex.. | Series B Preferred Stock | 1 | $20,000 | $20,000 | ||
Purchase | ALBANNA ROWENA officer: CHIEF OPERATING OFFICER | Common Stock | 3,400 | $2.92 | $9,942 | ||
Purchase | ALBANNA AMRO A. director, officer.. | Common Stock | 3,400 | $2.92 | $9,942 | ||
Purchase | SHABAHANG SHAHROKH director, officer: CHIEF INNOVA.. | Common Stock | 490 | $2.93 | $1,436 | ||
Purchase | RUNGE JEFFREY W. director | Common Stock | 10,000 | $2.94 | $29,360 | ||
Purchase | ALBANNA AMRO A. director, officer.. | Common Stock | 3,400 | $2.92 | $9,942 | ||
Purchase | ALBANNA ROWENA officer: CHIEF OPERATING OFFICER | Common Stock | 3,400 | $2.92 | $9,942 | ||
Purchase | SHABAHANG SHAHROKH director, officer: CHIEF INNOVA.. | Common Stock | 185 | N/A | N/A | ||
Purchase | FARLEY THOMAS J | Common Stock | 2,500 | $2.68 | $6,700 |
| Insider | Compensation |
|---|---|
Ms. Corinne D. Pankovcin CPA, CPA, M.B.A. (1966) Pres | $450,000 |
| Mr. Amro A. Albanna (1970) Co-Founder, Chairman & Chief Executive Officer | $252,000 |
Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. (1963) Co-Founder, Chief Innovation Officer, Sec. & Director | $210,000 |
-
What's the price of Aditxt stock today?
One share of Aditxt stock can currently be purchased for approximately $1.11.
-
When is Aditxt's next earnings date?
Unfortunately, Aditxt's (ADTX) next earnings date is currently unknown.
-
Does Aditxt pay dividends?
No, Aditxt does not pay dividends.
-
How much money does Aditxt make?
Aditxt has a market capitalization of 3.08M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 30.9% to 645.18K US dollars. Aditxt made a loss 32.38M US dollars in net income (profit) last year or -$48.77 on an earnings per share basis.
-
What is Aditxt's stock symbol?
Aditxt, Inc. is traded on the NASDAQ under the ticker symbol "ADTX".
-
What is Aditxt's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Aditxt?
Shares of Aditxt can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aditxt's key executives?
Aditxt's management team includes the following people:
- Ms. Corinne D. Pankovcin CPA, CPA, M.B.A. Pres(age: 59, pay: $450,000)
- Mr. Amro A. Albanna Co-Founder, Chairman & Chief Executive Officer(age: 55, pay: $252,000)
- Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. Co-Founder, Chief Innovation Officer, Sec. & Director(age: 62, pay: $210,000)
-
Is Aditxt founder-led company?
Yes, Aditxt is a company led by its founders Mr. Amro A. Albanna and Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D..
-
How many employees does Aditxt have?
As Jul 2024, Aditxt employs 47 workers, which is 23% less then previous quarter.
-
When Aditxt went public?
Aditxt, Inc. is publicly traded company for more then 5 years since IPO on 30 Jun 2020.
-
What is Aditxt's official website?
The official website for Aditxt is aditxt.com.
-
Where are Aditxt's headquarters?
Aditxt is headquartered at 737 North Fifth Street, Richmond, VA.
-
How can i contact Aditxt?
Aditxt's mailing address is 737 North Fifth Street, Richmond, VA and company can be reached via phone at +90 94880844.
Aditxt company profile:
Aditxt, Inc.
aditxt.comNASDAQ
47
Biotechnology
Healthcare
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Richmond, VA 23219
CIK: 0001726711
ISIN: US0070256047
CUSIP: 007025109
